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The state of the immune system is reflected, in part, by the
cell populations present in individual tissues which reflect
the tumor microenvironment (TME). Several studies have
suggested that understanding the TME constituents is
useful for predicting drug response outcomes. Despite the
biological significance of various inflammatory cell types
in the TME, a widely accepted quantitative paradigm that
allows the comparison of multiple subtypes of inflamma-
tory cells in tissues is lacking. This is largely due to our
inability to integrate key spatial information for multiple
biomarkers across whole tissue sections, understand the
concordance of individual biomarkers/cell types, account
for heterogeneity in the region of analysis, and the absence
of validated correlative scoring paradigms to measure
against drug response. Finally, if these hurdles of under-
standing are met, a system needs to be created which can
efficiently and reproducibly asses these readouts in a
clinical-use environment. In this study, we revealed by
immunohistochemistry distinct populations of immune
system cells on serial sections of clinical lung cancer
tissues. The immune cell markers evaluated included
CD68, CD33, CD11b, FoxP3, CD4, and CD8. Whole tissue
image analysis (tIA) was performed using Flagship’s
CellMap™ algorithm tool for each biomarker. Biomarker
expression was analyzed on cell by cell basis for the tumor
microenvironment and tabulated across the whole tissues.
In order to integrate spatial information of CD68, CD33,
CD11b, FoxP3, CD4, and CD8 biomarker expression from
each slide onto a single tissue section, we utilized
Flagship’s patented FACTS™ tIA tool. This tool allows for
an overlay of biomarker content information on to a single
reference slide (H&E), and thus can provide key spatial
information on biomarker expression relationships and
presence of distinct cell populations in relation to each
other. These studies directly demonstrate an effective utili-
zation of combination of IHC with a set of Flagship tIA-
based tools to score and analyze immune cell biomarker
content in whole clinical tissue samples. Importantly,
these tools can spatially correlate multiple biomarkers
across serial sections of a single tissue. These approaches
will lead to the development of standardized quantitative
paradigms with predictive power in evaluating patient
drug response.
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